ATP-binding cassette transporter A1 (ABCA1) plays an essential role in mediating cholesterol efflux to apolipoprotein A-I (apoA-I), a major housekeeping mechanism for cellular cholesterol homeostasis. After initial engagement with ABCA1, apoA-I directly interacts with the plasma membrane to acquire cholesterol. This apoA-I lipidation process is also known to require cellular signaling processes, presumably to support cholesterol trafficking to the plasma membrane. We report here that one of major signaling pathways in mammalian cells, Akt, is also involved. In several cell models that express ABCA1 including macrophages, pancreatic beta cells and hepatocytes, inhibition of Akt increases cholesterol efflux to apoA-I. Importantly, Akt inhibition has little effect on cells expressing non-functional mutant of ABCA1, implicating a specific role of Akt in ABCA1 function. Furthermore, we provide evidence that mTORC1, a major downstream target of Akt, is also a negative regulator of cholesterol efflux. In cells where mTORC1 is constitutively activated due to tuberous sclerosis complex 2 deletion, cholesterol efflux to apoA-I is no longer sensitive to Akt activity. This suggests that Akt suppresses cholesterol efflux through mTORC1 activation. Indeed, inhibition of mTORC1 by rapamycin or Torin-1 promotes cholesterol efflux. On the other hand, autophagy, one of the major pathways of cholesterol trafficking, is increased upon Akt inhibition. Furthermore, Akt inhibition disrupts lipid rafts, which is known to promote cholesterol efflux to apoA-I. We therefore conclude that Akt, through its downstream targets, mTORC1 and hence autophagy, negatively regulates cholesterol efflux to apoA-I.
Citation: Dong F, Mo Z, Eid W, Courtney KC, Zha X (2014) Akt Inhibition Promotes ABCA1-Mediated Cholesterol Efflux to ApoA-I through Suppressing mTORC1. PLoS ONE 9(11): e113789. https://doi.org/10.1371/journal.pone.0113789
Editor: Christopher Beh, Simon Fraser University, Canada
Received: August 1, 2014; Accepted: October 29, 2014; Published: November 21, 2014
Copyright: © 2014 Dong et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper.
Funding: This work is supported by a grant from Heart & Stroke Foundation of Ontario(T-7054) to XZ (http://www.hsf.ca/research/en/grants-aid) and in part by an operating grant from Canadian Institutes of Health Research (MOP-130453) to XZ (http://www.cihr-irsc.gc.ca/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Epidemiological studies have long established an inverse association between plasma HDL levels and coronary heart disease (CHD). However, simply raising total plasma HDL level has not been successful in preventing CHD , . This is thought to be due to substantial heterogeneity in plasma HDL. Only one sub-type, namely lipid poor pre-β HDL, is capable of efficiently removing excess cholesterol from the peripheral tissues including coronary arteries and thus offers protection for CHD. Indeed, a recent landmark study convincingly showed that the capacity of the plasma to remove cholesterol from cultured macrophages, which functions as a readout of plasma pre-β HDL contents, is the most effective indicator for CHD risks .
Pre-β HDL depends on ATP-binding cassette transporter A1 (ABCA1) to remove cholesterol. Identification of genetic defects causing Tangier disease has revealed a key role of ABCA1 –. Mutated ABCA1 fails to mediate cholesterol efflux to lipid poor pre-β HDL or its major protein apoA-I. Consequently, Tangier patients present much increased risk of CHD . Thus, enhancing ABCA1 function is likely a highly effective strategy to prevent CHD, parallel to raising pre-β HDL levels. However, the precise molecular mechanisms by which ABCA1 mediates cholesterol efflux to apoA-I remains elusive, which presents a major barrier for the development of pharmacological interventions.
Recent studies have implicated many signaling proteins in ABCA1 function and apoA-I lipidation . For example, greater than ten kinase pathways have already been proposed to modulate ABCA1 activity, including PKA, PKC, Cdc42, CK2 and JAK2 –. We reported earlier that apoA-I acquires cholesterol primarily at the plasma membrane . However, most excess cellular cholesterol in mammalian cells is stored as cholesterol ester (CE) in lipid droplets, such as those found in foam cells. One of the rate-limiting steps for cholesterol removal by ABCA1 is CE hydrolysis that supplies cholesterol to the plasma membrane . Efficient CE hydrolysis promotes ABCA1-mediated cholesterol efflux and reverses foam cell formation.
Recently, cholesterol efflux from macrophages was shown to require autophagy, a catabolic process that engulfs lipid droplets and delivers CE to the lysosomes for hydrolysis . Interestingly, autophagy is suppressed by mTORC1 , a master nutrient sensor that is hyper-activated in both diet-induced and genetically obese animals . In addition to nutrients (i.e. glucose and amino acids), mTORC1 is activated by growth factors through Akt . Akt phosphorylates tuberous sclerosis complex (TSC), an endogenous mTORC1 inhibitor, to disable TSC , . This leads to mTORC1 activation and autophagy suppression. Akt is therefore likely a negative-regulator of autophagy and potentially a negative regulator of ABCA1-mediated cholesterol efflux to apoA-I.
In this report, we tested the effect of Akt inhibition on ABCA1-mediated cholesterol efflux to apoA-I. Our results demonstrated for the first time that Akt negatively influences cholesterol efflux to apoA-I, most likely through its impact on TSC. We also show that Akt inhibition enhances autophagy and increases plasma membrane cholesterol accessibility to extracellular acceptors. We speculate that both processes contribute to more efficient cholesterol efflux to apoA-I.
Materials and reagents
Cell culture growth medium, antibiotics (penicillin/streptomycin, or P/S) and fetal bovine serum (FBS) were purchased from Invitrogen (Burlington, ON). Rabbit polyclonal anti-ABCA1 antibody was from Novus Biological Inc. (Littleton, CO). Rabbit polyclonal anti-Akt, -pAkt (ser473), -LC3, -flotillin-2 antibodies were from Cell Signaling. Rabbit monoclonal anti-pS6K was purchased from Millipore and rabbit polyclonal anti-S6K was from Santa Cruz. Anti-mouse HSP-70 monoclonal antibody was from BD Biosciences (Mississauga, ON) and peroxidase-conjugated sheep anti-mouse and donkey anti-rabbit IgGs from Jackson Immunoresearch Laboratories (West Grove, PA). [3H] cholesterol was purchased from PerkinElmer-Canada Inc. (Vaudreuil-Dorion, QC). Purified human apoA-I was from Biodesign International (Saco, ME). DEBC (10-[4'-(N,N-Diethylamino)butyl]-2-chlorophenoxazine hydrochloride) and Torin 1 were from Tocris Bioscience. Ly294002, Akt1/2 and rapamycin were from Sigma. Mifepristone, T0901317, methyl-β-cyclodextrin (MCD), bovine serum albumin (BSA) were from Sigma. Scintillation liquid ScintiSafe Gel Cocktail was from Fisher (Whitby, ON).
Baby hamster kidney (BHK) cell lines were generous gifts from Drs. Oram and Vaughan (University of Washington, Seattle, WA)  and RAW 264.7 macrophages (RAW), an adherent mouse macrophage cell line, was purchased from ATCC (Manassas, VA). BHK cells stably expressing an mifepristone-inducible vector with human ABCA1 (ABCA1) or mutant A937V ABCA1 (A937V) gene insert were prepared as described previously . RAW cells endogenously express ABCA1 upon induction with an LXR-agonist, T0901317. Min6, a pancreatic beta cell line, was from Dr. Screaton (Children's Hospital of Eastern Ontario, Ottawa) , whereas HepG2, a hepatic cell line, was from Dr. Lagace (University of Ottawa). Mouse embryonic fibroblasts (MEF), both wt and TSC2-/-, were generously provided by Dr. Guan (University of California, San Diego) .
All cell lines were maintained in Dulbecco's modified medium (DMEM) supplemented with 10% FBS and 1% P/S (100 units/mL penicillin and 100 µg/mL streptomycin) at 37°C in a 5% CO2 incubator. To induce ABCA1 expression, BHK cells were incubated for 18–20 hours with 10 nM mifepristone in DMEM plus 1 mg/ml BSA. Similarly, RAW, HepG2, Min 6 and MEFs were incubated 18–20 hours in DMEM/BSA medium plus 10 µM T0901317. In most of the experiments, Mock or mutant BHK cells and non-induced cells were used as negative controls.
Cells were seeded in 24-well plates and incubated with growth medium containing 1 µCi/ml [3H]-cholesterol for 24 hours to label cells to equilibrium. The medium was then replaced by fresh DMEM containing 1 mg/ml BSA plus mifepristone for BHK cells or T0901317 for other cell types as described above. For cholesterol efflux, cells were washed and incubated for 2 hours at 37°C either with apoA-I (5 µg/ml) in DMEM/BSA or without. At the end of the efflux period, the medium was collected and centrifuged at 500×g to remove detached cells and cell debris. The cell-free supernatant was then combined with scintillation liquid. The amount of [3H]-cholesterol in the medium was determined with scintillation counter (Beckman LS 6500) as counts per minute (cpm). The remaining adherent cells were lysed in 1 N NaOH overnight and the cpm of the lysate was measured. Efflux was expressed as the percent [3H]-cholesterol in the medium over total [3H]-cholesterol cholesterol (medium plus cell-associated).
Cells were placed on ice, washed twice with cold PBS and then lysed with SDS buffer (50 mM Tris-Cl pH 6.8, 100 mM dithiothreitol, 2% SDS, 10% glycerol, and 1 tablet each protease and phosphatase inhibitor per 10 mL buffer). A volume of 100 µL lysis buffer was used in each of 60 mm dishes. Lysates were sonicated for 10–15 seconds to shear DNA and then heated to 75°C for 5 min. Lysates were then centrifuged for 1 min at 13,000 g and protein contents in the supernatant were quantified. For electrophoresis, samples were prepared by mixing 4× SDS loading buffer (200 mM Tris HCl, pH 6.8, 400 mM dithiothreitol, 8% SDS, 40% glycerol, 0.4% bromophenol blue) with 15–25 µg of cell lysates. Samples were loaded onto 10% acrylamide resolving gels (10% acrylamide mix (9.67% acrylamide, 0.33% bis). Separated proteins were transferred to PVDF membranes. PVDF membranes were blocked with TBS-T (50 mM Tris HCl, pH 7.4, 150 mM NaCl, 0.1% Tween-20) containing 2.5% BSA for 30 min and then incubated with primary antibody with gentle agitation overnight at 4°C. After 3 washes with TBS-T (5 min each), membrane was incubated and gently agitated for 2 hours in secondary antibody in TBS-T with 1% BSA. PVDF membranes were then incubated for 1 minute with 1 mL chemiluminescent substrate and developed with x-ray film.
Lipid analysis for free cholesterol and cholesterol ester
BHK cells were seeded in 6-well plates. After incubated with 1 mg/ml BSA/DMEM plus 10 nM mifepristone for 18 hours, cells were treated with 50 µM DEBC for 2 hours. Then 1000 µl isopropanol was added to each well, rocked at room temperature for 10 minutes and put at 4°C for overnight. Collect the isopropanol to glass tubes and dry down under N2 for 90 minutes. The dried samples were diluted by 500 µl 1× Reaction Buffer from an Amplex Red Cholesterol Assay Kit, Invitrogen. A volume of 50 µl was used for each reaction. Meanwhile, 1000 µl NaOH (1 M) were added to each wells for solubilizing cells and measuring the protein concentration after removed the isopropanol. Total cholesterol (TC) and free cholesterol (FC) was measured by a commercial cholesterol assay kit (Amplex Red Cholesterol Assay Kit, Invitrogen) according to the manufacturer's instruction.
Detergent-free sucrose gradient floatation
The analysis was carried out following an established protocol . Briefly, BHK cells from 10-cm dish after PBS-wash were scraped into 500 ul buffer A (500 mM sodium carbonate, 150 mM NaCl, pH 11). Homogenization was carried out by a sonicator (two 10-s bursts). The homogenate with 1.5 mg of proteins in 2 ml buffer A were mixed with 2 ml buffer B (80% sucrose, 25 mM MES, 150 mM NaCl, pH 6.5), then placed at the bottom of an ultracentrifuge tube. A 5–40% discontinuous sucrose gradient was overlaid above (4 ml of 5% sucrose/4 ml of 40% sucrose; both in a buffer containing 250 mM sodium carbonate, 25 mM MES, 150 mM NaCl, pH 6.5). The samples were centrifuged at 39000 rpm at 4°C for 20 h. 12 fractions of 1 ml each from the top to bottom of the tube were collected.
For probing membrane protein markers in the fractions , 0.8 ml of methanol were added to each 0.2 ml of sucrose gradient fractions in an eppendorf tube. Samples were vortexed and centrifuged at 9000 g for 10 sec. 0.2 ml of chloroform were added to each sample followed by vortex and centrifugation for 10 sec. After adding 0.6 ml of water, samples were vortexed and centrifuged at 13000 rpm for 1 min. The upper phase was removed and discarded. 0.6 ml of methanol was added to the rest of lower phase and interphase. The samples were mixed and centrifuged at 13000 rpm for 2 min. The supernatant was removed and the protein pellets were dried under speedvac. Proteins were then solubilised in SDS buffer for SDS-PAGE analysis.
Statistical comparisons between groups were performed with PRISM software (GraphPad InStat v3.05). All other data are presented as mean ± standard deviation (SD). The statistical significance of differences between groups was analyzed by Student's t -test. Differences were considered significant at a P value <0.05.
In searching for intracellular targets that enhance ABCA1 function, we tested various inhibitors using BHK cells that inducibly express wt and mutant ABCA1, a well-established cell model for ABCA1 study . We found that Akt inhibition specifically increases cholesterol efflux to apoA-I in an ABCA1-dependent manner. As shown in Fig. 1, Akt inhibitor DEBC dose-dependently inhibits Akt phosphorylation without changing ABCA1 expression (Fig. 1 A). DEBC also leads to a dose-dependent increase of cholesterol efflux to apoA-I (Fig. 1 B). Significantly, DEBC is only able to enhance cholesterol efflux from cells expressing fully functional ABCA1. It has little effect on BHK cells with no ABCA1 expression (data not shown) or BHK cells expressing a dysfunctional mutant form of ABCA1 (A937V) (Fig. 1 C). Similarly, LY294002, an inhibitor of PI3 kinase upstream of Akt, potently inhibits Akt phosphorylation and enhances cholesterol efflux (Fig. 2 A & B). Furthermore, another structurally unrelated Akt inhibitor, Akt1/2, is also able to promote cholesterol efflux (Fig. 2 C). Thus, inhibition of Akt promotes cholesterol efflux and this action is specific to ABCA1.
A) BHK-ABCA1 cells were induced with mifepristone (10 nM) overnight and then incubated with indicated doses of DEBC for 2 h. Cells were then lysed and Western-blotted for ABCA1, phosphorylated Akt (p-Akt) and total Akt. Hsp70 was also blotted as loading control. B) BHK-ABCA1 cells were labeled with [3H] cholesterol and induced overnight as above. After 2 h incubation with BSA (1 mg/ml) or BSA plus apoA-I (5 µg/ml), cholesterol efflux was measured as described in the Methods section. Some of the cells were also incubated with indicated doses of DEBC, in addition to apoA-I, during 2 h efflux period. C) BHK-ABCA1 and BHK-A937V cells were induced with mifepristone (10 nM) overnight. 2 h Cholesterol efflux was measured as above either with or without DEBC (25 µM). Results are presented as the average of triplicate wells with standard deviation and representative of more than three independent experiments. *** P<0.0001 and **P<0.001 vs apoA-I only.
A) BHK cells were induced as in Fig. 1 and then incubated with LY294002 (200 µM) for 2 h. Cells were then lysed and analysed for ABCA1, phosphorylated Akt (p-Akt) and total Akt by Western-blotting. Hsp70 was also blotted as loading control. B & C) BHK cells were labeled with [3H] cholesterol and induced with 10 nM mifepristone overnight. Cholesterol efflux was measured after 2 h incubation with BSA (1 mg/ml) or BSA plus apoA-I (5 µg/ml). Some of cells were also incubated with indicated doses of LY294002 (B) or Akt1/2 (C), in addition to apoA-I, during 2 h efflux period. Results are presented as the average of triplicate wells with standard deviation and representative of more than three independent experiments. *** P<0.0001, **P<0.001 and *P<0.05 vs apoA-I only.
We then tested whether the Akt effect is applicable to other cell types known to express endogenous ABCA1. As shown in Fig. 3, DEBC is able to boost cholesterol efflux to apoA-I from RAW (macrophages), Min 6 (pancreatic beta cells) and HepG2 (hepatocytes), which suggests a rather general impact of Akt on cholesterol efflux process, not at all limiting to ABCA1-expressing BHK cells.
Raw macrophages, Min6 and HepG2 cells were labeled with [3H] cholesterol for 1 day and then incubated with T0901317 (10 µM) overnight. Cholesterol efflux was then performed with or without apoA-I (10 µg/ml) for 2 h. Some of the cells were also incubated with DEBC (50 µM), in addition to apoA-I, during 2 h efflux period. Results are presented as the average of triplicate wells with standard deviation and representative of more than three independent experiments. *** P<0.0001 and **P<0.001 vs apoA-I only.
We next searched for downstream targets of Akt that might be involved in regulating cholesterol efflux. One of the potential targets is mTORC1, a key regulator of wide range of metabolic functions including lipogenesis . We first investigated whether Akt inhibitors influence mTORC1 activity. As shown in Fig 4, both LY294002 and DEBC suppress mTORC1 activity, evidenced by decreased phosphorylation of S6K, an mTORC1 target (lane 2–8). An mTORC1 inhibitor, rapamycin, also suppresses S6K phosphorylation (lane 9–11), as expected. Curiously, although LY294002 potently blocked S6K phosphorylation at low concentrations, such as 20 and 50 µM, cholesterol efflux to apoA-I was not affected at these concentrations (data not shown).
BHK-ABCA1 cells were induced overnight with mifepristone (10 nM) and then incubated with DEBC, LY294002 or rapamycin at indicated concentrations for 2 h. Cells were then lysed and analyzed for ABCA1 and phosphorylated S6K by Western blotting. Actin was also blotted as loading control.
We next asked whether Akt requires mTORC1 to exert its negative regulation on cholesterol efflux to apoA-I. mTORC1 activity is suppressed by tuberous sclerosis proteins 1 and 2 complex (TSC1/2). Activated Akt phosphorylates TSC1/2 to release this suppression, whereby activating mTORC1 , . Consequently, deletion of TSC1 or TSC2 (both are required for complex formation) leads to constitutive mTORC1 activation, regardless of upstream signals . Consistent with this notion, mTORC1 activity in TSC2-/- MEFs is persistently elevated, shown by high p-S6K levels (Fig. 5 A). Similar to its effect in other cell types, DEBC blocks Akt activation and increases cholesterol efflux to apoA-I in wt MEFs (Fig. 5 C, left three columns). In TSC2-/- MEFs, Akt activity is low (Fig. 5 B, right columns), due to a feedback regulatory mechanism . Still, TSC2-/- MEFs are less efficient in cholesterol efflux to apoA-I, regardless of the lower basal Akt activity. Importantly, DEBC is no longer able to enhance cholesterol efflux to apoA-I in TSC2-/- MEFs. ABCA1 is similarly expressed in TSC2-/- MEFs as in wt MEFs. This supports the notion that mTORC1 is downstream of Akt in suppressing cholesterol efflux to apoA-I.
A) Mouse embryonic fibroblasts (MEFs), wt and TSC2-/-, were induced overnight with T0901317 (10 µM). Cell lysates were collected for Western blotting for phosphorylated S6K and total S6K. B) wt and TSC2-/- MEFs were incubated with or without T0901317 (10 µM) overnight. Some of cells were then incubated with apoA-I (10 µg/ml) or apoA-I plus DEBC (25 µM) for 2 h. The expression of ABCA1, phosphorylated Akt, total Akt and loading control hsp70 were analyzed by Western blotting. C) wt and TSC2-/- were labeled with [3H] cholesterol for 1 day and then incubated with or without T0901317 (10 µM) overnight. Some of cells were then incubated with apoA-I (10 µg/ml) or apoA-I plus DEBC (25 µM) for 2 h to analyze cholesterol efflux. Data presented as the average of triplicate wells with standard deviation and representative of at least three independent experiments. *** P<0.0001 vs apoA-I only.
To further confirm the involvement of mTORC1, we next tested the effect of mTORC1 inhibitors. Two commonly used mTORC1 inhibitors, rapamycin and Torin-1, are able to enhance cholesterol efflux to apoA-I in ABCA1-expressing BHK cells (Fig. 6 A & B). Additionally, rapamycin has limited effect on DEBC treated wt MEFs, presumably because mTORC1 is already suppressed. However, in TSC-/- MEFs, rapamycin significantly enhances cholesterol efflux (Fig. 6 C), though it is still short of full recovery. Both rapamycin and Torin-1 are known to only partially block mTORC1 functions , which could explain the partial recovery of cholesterol efflux by rapamycin above. Nevertheless, together with the results from TSC2-/- MEFs, this set of experiments further supports mTORC1 as the downstream effector of Akt, through which Akt suppresses cholesterol efflux to apoA-I.
A&B) BHK-ABCA1 cells were labeled with [3H] cholesterol for one day and induced with mifepristone (10 nM) overnight. Cholesterol efflux was measured as the percentage of [3H] cholesterol in the medium after 2 h incubation with apoA-I (5 µg/ml) with or without (A) rapamycin (20 nM) or (B) Torin-1 (250 nM). C) MEFs, wt and TSC2-/-, were labeled with [3H] cholesterol for 1 day and then incubated with or without T0901317 (10 µM) overnight. Cells were then incubated with apoA-I (10 µg/ml), DEBC (25 µM) and with or without rapamycin (20 nM) for 2 h to analyze cholesterol efflux. Data presented as the average of triplicate wells with standard deviation and representative of at least three independent experiments. *** P<0.0001, **P<0.001 and *P<0.05.
As mentioned earlier, activated mTORC1 is known to suppress autophagy . Autophagy is recently reported to promote intracellular cholesterol trafficking in macrophages, thereby facilitating ABCA1-mediated cholesterol efflux to apoA-I . Interestingly, PI3K also suppresses autophagy, although it could also promote autophagy under various circumstances . We therefore tested whether Akt inhibition by LY294002 or DEBC stimulated autophagy. Autophagic function is commonly detected by the lipidation of LC3, which converts LC3-I to LC3-II . More LC3-II relative to LC3-I (hence lower the ratio of LC3-I/LC3-II) indicates higher autophagy activity. Judging from the ratio of LC3-I over LC3-II, DEBC consistently enhanced autophagy (Fig. 7 A). LY294002 also accelerated autophagy, but only at high concentrations (100 and 200 µM). This is in agreement with our observation that LY294002 only promotes cholesterol efflux at higher dosages (Fig. 2). In addition, increased autophagy should facilitate hydrolysis of cholesterol ester (CE). We indeed observed significant decrease of CE mass with correspondent increase in free cholesterol (FC) contents in cells treated with DEBC for 2 h, in comparison with control cells (Fig. 7 B). Noticeably, this decrease occurs in the absence of apoA-I. Hence, it could not be due to net loss of cholesterol through efflux from cells (see Fig. 1 C). It is thus likely that cellular free cholesterol (FC) pool is enlarged by Akt inhibition. An enlarged FC pool could in theory lead to more cholesterol supplied to the plasma membrane and hence more cholesterol efflux to apoA-I.
A) BHK-ABCA1 cells were induced overnight with mifepristone (10 nM) and then incubated with DEBC or LY294002 at indicated concentrations for 2 h. Cells were then lysed and analyzed for LC3 by Western blotting. Actin was also blotted as loading control. The ratio of LC3-I/LC3-II is presented in the top row. B) BHK-ABCA1 cells were treated with DEBC or without for 2 h before lipid extraction and cholesterol mass analysis. Data represents the average of three independent experiments with standard deviation. **P<0.01.
It is also known that apoA-I prefers relatively loosely packed membranes or non-lipid-rafts for its lipidation , . We reported previously that ABCA1 is able to generate non-lipid-raft domains , perhaps by promoting phospholipid flip-flop . Akt inhibition could introduce further changes in the plasma membrane, thereby promoting cholesterol efflux to apoA-I. We therefore next characterized the plasma membrane microdomain structures.
First, membrane domains were separated by detergent-free density floatation. As shown in Fig. 8 row A, a large portion of flotillin-2, a commonly used lipid raft marker, is in the light density fractions or lipid rafts (fraction 5–7). Upon cholesterol depletion by MCD (5 mM, 30 min), flotillin-2 disappears from these light fractions (row B). Flotillin-2 reappears when cholesterol was replenished by a 90 min incubation with cholesterol/MCD complexs (row C), which is consistent with its being a lipid-raft marker. As mentioned above, DEBC by itself in the absence of apoA-I does not influence cholesterol efflux (no net change of cellular cholesterol contents). However, 2 h DEBC incubation is able to release flotillin-2 from light fractions (row D), similar to cholesterol depleted cells. This suggests a specific disruption of lipid rafts by DEBC.
ABCA1-expressing BHK cells were untreated (A), treated with 5 mM MCD for 30 min to deplete cholesterol (B) or treated with 5 mM MCD (30 min) and then 5 mM cholesterol/MCD complex (90 min) (C). Some of the cells were also treated with DEBC (50 µM) for 2 h (D). Cells were then collected for density floatation as described in the Methods section. The fractions were then analyzed by Western blotting for flotillin-2. Data is representative of more than three independent experiments.
We have previously demonstrated that one function of ABCA1 is to disrupt lipid rafts without altering cholesterol levels in the plasma membrane  and this change of cholesterol packing is necessary for cholesterol efflux to apoA-I . We therefore further tested whether Akt inhibition similarly influenced cholesterol packing in the plasma membrane. Experimentally, this is achieved by cholesterol extraction with MCD for 1 min at 37°C or 30 min at 0°C. 1 min MCD extraction at 37°C is designed to effectively remove plasma membrane cholesterol without significant contribution from intracellular cholesterol pools, thereby assessing plasma membrane cholesterol contents. 30 min MCD extraction at 0°C, on the other hand, preferentially removes cholesterol from loosely packed membranes or non-lipid-raft fractions .
Consistent with our previous reports, ABCA1 expression increases the amount of cholesterol extracted by MCD at 0°C (Fig. 9 A) but, at 37°C, 1 min MCD removes the equal amount of cholesterol, regardless of ABCA1 expression (Fig. 9 B). DEBC treatment does not alter ABCA1 expression (Fig. 1 A) or plasma membrane cholesterol levels, judging by 1 min cholesterol extraction at 37°C (Fig. 9 B). However, it significantly enhances the amount of cholesterol extracted by MCD at 0°C (Fig. 9 A). Together with the density floatation experiment above (Fig. 8), it is plausible that Akt inhibition by DEBC further disrupts lipid rafts in the plasma membrane of ABCA1-expressing cells. This expands the membrane fractions favorable for apoA-I to interact with, which leads to more efficient cholesterol efflux.
A) BHK-ABCA1 cells were labeled with [3H] cholesterol for one day and induced with mifepristone (10 nM) overnight. Cells were then treated with or without DEBC (50 µM) for 2 h before 30 min incubation with MCD at 0°C. Medium was collected and [3H] cholesterol in the medium was normalized with total cell associated [3H] cholesterol and presented as percentage extraction. B) BHK-ABCA1 cells were similarly treated as in A, except that MCD extraction was performed at 37°C for 1 min. Data presented as the average of triplicate wells with standard deviation and representative of at least three independent experiments.
In this report, we presented several lines of evidence indicating that Akt negatively regulated ABCA1 function. First, three structurally unrelated Akt inhibitors all significantly increase cholesterol efflux to apoA-I. This effect was strictly ABCA1-dependent, as Akt inhibitors had no effect on either non-ABCA1 expressing cells or cells expressing a defective mutant of ABCA1.
Secondly, the effect of Akt inhibition was applicable to various cell types that express endogenous ABCA1, including macrophages, pancreatic β cells, hepatocytes and MEFs. Cholesterol efflux to apoA-I is known to be essential for maintaining physiological functions in these cell types, as tissue-specific ABCA1 deletion results in foam cell formation (macrophages) , diabetes (pancreatic β cells)  and extremely low HDL (hepatocytes) .
Third, Akt requires mTORC1 to suppress cholesterol efflux to apoA-I. Indeed, the effect of Akt inhibitor was largely muted in TSC2-/- cells, where mTORC1 activity is constitutively elevated and no longer subject to Akt regulation. TSC2-/- cells was also unable to efficiently efflux cholesterol to apoA-I, even though ABCA1 was adequately expressed.
Forth, the connection between Akt and cholesterol efflux was likely autophagy. mTORC1 is one of the major regulators of autophagy. Elevated mTORC1 activity could suppress autophagy and Akt inhibition, on the other hand, could effectively release this suppression. We indeed observed increased LC3-II and decreased CE contents upon Akt inhibition. Interestingly, low doses of LY294002 could block mTORC1 activation (Fig. 4) but failed to effectively activate autophagy (Fig. 7 A). This is consistent with our observation that only high dosages of LY294002 were able to enhance cholesterol efflux (Fig. 2 B). Lastly, Akt inhibition enlarges the non-lipid raft pool of the plasma membrane, which supports increased capacity to efflux cholesterol to apoA-I.
Taken together, we conclude that Akt is a significant regulator of ABCA1 function, such as cholesterol efflux to apoA-I. Akt inhibition most likely accelerates autophagy through suppressing mTORC1, whereby increasing CE hydrolysis and intracellular cholesterol trafficking. Akt inhibition also generates a well-conditioned plasma membrane (less lipid rafts), which enables apoA-I to acquire cholesterol more efficiently.
It should be emphasized that our conclusion is primarily derived from pharmacological studies. As almost always, pharmacological inhibitors could have significant off-target effects, even if they are structurally unrelated. We therefore could not entirely rule out off-target effects by these Akt inhibitors. However, pharmacological inhibitors do have the advantage of acting acutely, such as 2 h used in this study, which offers a unique window of opportunity to delineate the primary effects of target proteins. This is in contrast with long-term inhibition as in genetic ablation or knockdown. For major signaling hubs like Akt, long-term knockout or even knockdown could trigger significant compensatory mechanisms. In this regard, pharmacological inhibitors should be an important and necessary part of research, in addition to genetic manipulations, in order to fully understand the precise sequences of events.
In mammalian cells, Akt is a family of three serine/threonine protein kinases (Akt1, Akt2 and Akt3) that regulate a wide range of cellular functions, including cell survival, proliferation, differentiation and metabolism , . These isoforms share the same domain structures and a very high sequence homology. Although the majority of research does not distinguish isoforms, it is increasingly evident that each isoform has significant non-overlapping functions. Most strikingly, individual Akt1, Akt2 or Akt3 knockout mice exhibit distinct phenotypes including metabolic and lipogenesis dysregulation –. We do not currently understand which Akt isoform might be involved in suppressing cholesterol efflux to apoA-I. Isoform-specific antibodies and, particularly, antibodies against phosphorylated Akt isoforms, are either not currently available or of high enough quality for detailed studies in our hands (data not shown). Nevertheless, it is interesting to note that casein kinase 2 (CK2) suppresses cholesterol efflux to apoA-I . CK2 is recently shown to specifically phosphorylate and activate Akt1 . It remains to be seen if CK2 requires Akt1 to suppress ABCA1 function. It is also noteworthy that Akt2 ablation, not Akt1, is reported to promote alternative activation (M2) in macrophages . We recently show that ABCA1 could similarly promote M2 polarization, parallel to its function in cholesterol efflux . It is not clear yet whether ABCA1 directly modulates Akt activities, particularly the activities of each isoform. Akt is mostly studied and understood in the context of cancer. Even there, it is increasingly apparent that each of Akt isoforms plays highly specific and frequently opposing roles. Another important advance in recent years is the distinct roles that each Akt isoform plays in metabolic diseases and atherosclerosis –. Future studies are required to explore whether and how ABCA1 or cholesterol influences the Akt activities in an isoform-specific manner and vice versa.
Interestingly, there is a growing body of evidence that growth factors through PI3K/Akt directly influence lipid metabolism . For example, insulin activates SREBP1-c through mTORC1 . Although most studies have focused on SREBP-1c, insulin signaling was recently shown to be necessary for SREBP-2 activation , which is also consistent with earlier observations that Akt directly activates SREBP-2 . Thus, it is not surprising that growth factors through PI3K/Akt may also suppress cholesterol efflux pathways, in parallel with their role in activating cholesterol/phospholipid synthesis.
In summary, the present study implicates the negative involvement of Akt signaling in ABCA1-mediated cholesterol efflux to apoA-I. Given that mTORC1 mediates this negative regulation, our study suggests a significant interaction between cellular cholesterol homeostasis and metabolic regulation.
We thank Dr. KL Guan (University of California, San Diego) for generously providing wt and TSC2-/- MEFs and Dr. DJ Kwiatkowsky (Harvard Medical School) for the permission to use these cells. This work was supported in part by an operating grant from Canadian Institutes of Health Research (MOP-130453). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Conceived and designed the experiments: FD XZ. Performed the experiments: FD ZM WE KC. Analyzed the data: FD ZM KC XZ. Wrote the paper: FD KC XZ.
- 1. Singh IM, Shishehbor MH, Ansell BJ (2007) High-density lipoprotein as a therapeutic target: a systematic review. JAMA 298:786–798.
- 2. Briel M, Ferreira-Gonzalez I, You JJ, Karanicolas PJ, Akl EA, et al. (2009) Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 338:b92.
- 3. Khera AV, Cuchel M, Llera-Moya M, Rodrigues A, Burke MF, et al. (2011) Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 364:127–135.
- 4. Bodzioch M, Orso E, Klucken J, Langmann T, Bottcher A, et al. (1999) The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet 22:347–351.
- 5. Brooks-Wilson A, Marcil M, Clee SM, Zhang LH, Roomp K, et al. (1999) Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet 22:336–345.
- 6. Orso E, Broccardo C, Kaminski WE, Bottcher A, Liebisch G, et al. (2000) Transport of lipids from golgi to plasma membrane is defective in tangier disease patients and Abc1-deficient mice. Nat Genet 24:192–196.
- 7. Rust S, Rosier M, Funke H, Real J, Amoura Z, et al. (1999) Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet 22:352–355.
- 8. Oram JF, Vaughan AM (2006) ATP-Binding cassette cholesterol transporters and cardiovascular disease. Circ Res 99:1031–1043.
- 9. Luu W, Sharpe LJ, Gelissen IC, Brown AJ (2013) The role of signalling in cellular cholesterol homeostasis. IUBMB Life 65:675–684.
- 10. Haidar B, Denis M, Krimbou L, Marcil M, Genest J Jr (2002) cAMP induces ABCA1 phosphorylation activity and promotes cholesterol efflux from fibroblasts. J Lipid Res 43:2087–2094.
- 11. Kiss RS, Maric J, Marcel YL (2005) Lipid efflux in human and mouse macrophagic cells: evidence for differential regulation of phospholipid and cholesterol efflux. J Lipid Res 46:1877–1887.
- 12. Nofer JR, Feuerborn R, Levkau B, Sokoll A, Seedorf U, et al. (2003) Involvement of Cdc42 signaling in apoA-I-induced cholesterol efflux. J Biol Chem 278:53055–53062.
- 13. Roosbeek S, Peelman F, Verhee A, Labeur C, Caster H, et al. (2004) Phosphorylation by protein kinase CK2 modulates the activity of the ATP binding cassette A1 transporter. J Biol Chem 279:37779–37788.
- 14. Tang C, Vaughan AM, Oram JF (2004) Janus kinase 2 modulates the apolipoprotein interactions with ABCA1 required for removing cellular cholesterol. J Biol Chem 279:7622–7628.
- 15. Wang Y, Oram JF (2007) Unsaturated fatty acids phosphorylate and destabilize ABCA1 through a protein kinase C delta pathway. J Lipid Res 48:1062–1068.
- 16. Yamauchi Y, Hayashi M, Abe-Dohmae S, Yokoyama S (2003) Apolipoprotein A-I activates protein kinase C alpha signaling to phosphorylate and stabilize ATP binding cassette transporter A1 for the high density lipoprotein assembly. J Biol Chem 278:47890–47897.
- 17. Martinez LO, Agerholm-Larsen B, Wang N, Chen W, Tall AR (2003) Phosphorylation of a pest sequence in ABCA1 promotes calpain degradation and is reversed by ApoA-I. J Biol Chem 278:37368–37374.
- 18. Denis M, Landry YD, Zha X (2008) ATP-binding cassette A1-mediated lipidation of apolipoprotein A-I occurs at the plasma membrane and not in the endocytic compartments. J Biol Chem 283:16178–16186.
- 19. Oram JF, Yokoyama S (1996) Apolipoprotein-mediated removal of cellular cholesterol and phospholipids. J Lipid Res 37:2473–2491.
- 20. Ouimet M, Franklin V, Mak E, Liao X, Tabas I, et al. (2011) Autophagy regulates cholesterol efflux from macrophage foam cells via lysosomal acid lipase. Cell Metab 13:655–667.
- 21. Moscat J, Diaz-Meco MT (2011) Feedback on fat: p62-mTORC1-autophagy connections. Cell 147:724–727.
- 22. Ai D, Baez JM, Jiang H, Conlon DM, Hernandez-Ono A, et al. (2012) Activation of ER stress and mTORC1 suppresses hepatic sortilin-1 levels in obese mice. J Clin Invest 122:1677–1687.
- 23. Kwiatkowski DJ (2003) Tuberous sclerosis: from tubers to mTOR. Ann Hum Genet 67:87–96.
- 24. Potter CJ, Pedraza LG, Huang H, Xu T (2003) The tuberous sclerosis complex (TSC) pathway and mechanism of size control. Biochem Soc Trans 31:584–586.
- 25. Inoki K, Li Y, Zhu T, Wu J, Guan KL (2002) TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4:648–657.
- 26. Vaughan AM, Oram JF (2003) ABCA1 redistributes membrane cholesterol independent of apolipoprotein interactions. J Lipid Res 44:1373–1380.
- 27. Jansson D, Ng AC, Fu A, Depatie C, Al AM, et al. (2008) Glucose controls CREB activity in islet cells via regulated phosphorylation of TORC2. Proc Natl Acad Sci U S A 105:10161–10166.
- 28. McNutt MC, Kwon HJ, Chen C, Chen JR, Horton JD, et al. (2009) Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells. J Biol Chem 284:10561–10570.
- 29. Kang YJ, Lu MK, Guan KL (2011) The TSC1 and TSC2 tumor suppressors are required for proper ER stress response and protect cells from ER stress-induced apoptosis. Cell Death Differ 18:133–144.
- 30. Song KS, Li S, Okamoto T, Quilliam LA, Sargiacomo M, et al. (1996) Co-purification and direct interaction of Ras with caveolin, an integral membrane protein of caveolae microdomains. Detergent-free purification of caveolae microdomains. J Biol Chem 271:9690–9697.
- 31. Wessel D, Flugge UI (1984) A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids. Anal Biochem 138:141–143.
- 32. Yang Q, Inoki K, Kim E, Guan KL (2006) TSC1/TSC2 and Rheb have different effects on TORC1 and TORC2 activity. Proc Natl Acad Sci U S A 103:6811–6816.
- 33. Thoreen CC, Chantranupong L, Keys HR, Wang T, Gray NS, et al. (2012) A unifying model for mTORC1-mediated regulation of mRNA translation. Nature 485:109–113.
- 34. Farrell O, Rusten TE, Stenmark H (2013) Phosphoinositide 3-kinases as accelerators and brakes of autophagy. FEBS J 280:6322–6337.
- 35. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, et al. (2012) Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 8:445–544.
- 36. Landry YD, Denis M, Nandi S, Bell S, Vaughan AM, et al. (2006) ATP-binding cassette transporter A1 expression disrupts raft membrane microdomains through its ATPase-related functions. J Biol Chem 281:36091–36101.
- 37. Vedhachalam C, Duong PT, Nickel M, Nguyen D, Dhanasekaran P, et al. (2007) Mechanism of ATP-binding cassette transporter A1-mediated cellular lipid efflux to apolipoprotein A-I and formation of high density lipoprotein particles. J Biol Chem 282:25123–25130.
- 38. Hamon Y, Broccardo C, Chambenoit O, Luciani MF, Toti F, et al. (2000) ABC1 promotes engulfment of apoptotic cells and transbilayer redistribution of phosphatidylserine. Nat Cell Biol 2:399–406.
- 39. Nandi S, Ma L, Denis M, Karwatsky J, Li Z, et al. (2009) ABCA1-mediated cholesterol efflux generates microparticles in addition to HDL through processes governed by membrane rigidity. J Lipid Res 50:456–466.
- 40. van Eck M, Bos IS, Kaminski WE, Orso E, Rothe G, et al. (2002) Leukocyte ABCA1 controls susceptibility to atherosclerosis and macrophage recruitment into tissues. Proc Natl Acad Sci U S A 99:6298–6303.
- 41. Brunham LR, Kruit JK, Pape TD, Timmins JM, Reuwer AQ, et al. (2007) Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat Med 13:340–347.
- 42. Timmins JM, Lee JY, Boudyguina E, Kluckman KD, Brunham LR, et al. (2005) Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J Clin Invest 115:1333–1342.
- 43. Fernandez-Hernando C, Ackah E, Yu J, Suarez Y, Murata T, et al. (2007) Loss of Akt1 leads to severe atherosclerosis and occlusive coronary artery disease. Cell Metab 6:446–457.
- 44. Iliopoulos D, Polytarchou C, Hatziapostolou M, Kottakis F, Maroulakou IG, et al. (2009) MicroRNAs differentially regulated by Akt isoforms control EMT and stem cell renewal in cancer cells. Sci Signal 2:ra62.
- 45. Ding L, Biswas S, Morton RE, Smith JD, Hay N, et al. (2012) Akt3 deficiency in macrophages promotes foam cell formation and atherosclerosis in mice. Cell Metab 15:861–872.
- 46. Cho H, Mu J, Kim JK, Thorvaldsen JL, Chu Q, et al. (2001) Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science 292:1728–1731.
- 47. Cho H, Thorvaldsen JL, Chu Q, Feng F, Birnbaum MJ (2001) Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J Biol Chem 276:38349–38352.
- 48. Girardi C, James P, Zanin S, Pinna LA, Ruzzene M (2014) Differential phosphorylation of Akt1 and Akt2 by protein kinase CK2 may account for isoform specific functions. Biochim Biophys Acta 1843:1865–1874.
- 49. Arranz A, Doxaki C, Vergadi E, Martinez dlT, Vaporidi K, et al. (2012) Akt1 and Akt2 protein kinases differentially contribute to macrophage polarization. Proc Natl Acad Sci U S A 109:9517–9522.
- 50. Ma L, Dong F, Zaid M, Kumar A, Zha X (2012) ABCA1 protein enhances Toll-like receptor 4 (TLR4)-stimulated interleukin-10 (IL-10) secretion through protein kinase A (PKA) activation. J Biol Chem 287:40502–40512.
- 51. Krycer JR, Sharpe LJ, Luu W, Brown AJ (2010) The Akt-SREBP nexus: cell signaling meets lipid metabolism. Trends Endocrinol Metab 21:268–276.
- 52. Li S, Brown MS, Goldstein JL (2010) Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. Proc Natl Acad Sci U S A 107:3441–3446.
- 53. Miao J, Haas JT, Manthena P, Wang Y, Zhao E, et al. (2014) Hepatic insulin receptor deficiency impairs the SREBP-2 response to feeding and statins. J Lipid Res 55:659–667.
- 54. Luu W, Sharpe LJ, Stevenson J, Brown AJ (2012) Akt acutely activates the cholesterogenic transcription factor SREBP-2. Biochim Biophys Acta 1823:458–464.